- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05557695
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom (EPIC)
February 14, 2024 updated by: AstraZeneca
A Non-interventional, Observational Cohort Study of Chronic Lymphocytic Leukaemia Patients Treated With Acalabrutinib in the First-line Setting Through the UK Early Access Programme: Early Access Programme Outcomes In aCalabrutinib (EPIC).
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study).
Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients.
Clinical data will be extracted from the patients' clinical records in line with local laws.
Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Primary Objectives:
a. To estimate real-world progression-free survival in patients with CLL who received acalabrutinib in the first-line.
Secondary Objectives:
- To estimate real-world overall survival in patients with CLL who received acalabrutinib in the first-line.
- To describe real-world response rate to acalabrutinib in patients with CLL who received acalabrutinib in the first-line.
- To describe the healthcare resource utilisation in patients with CLL who received acalabrutinib in the first-line.
- To describe post-progression treatment patterns in patients with CLL who progressed from first-line acalabrutinib.
- To describe real-world clinical progression free survival in patients with CLL who received acalabrutinib in the first-line and progressed during acalabrutinib treatment.
- To describe acalabrutinib treatment patterns in patients with CLL who received acalabrutinib in the first-line.
- To describe baseline clinical and demographic characteristics in patients with CLL who received acalabrutinib in the first-line.
Study Type
Observational
Enrollment (Estimated)
350
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Aylesbury, United Kingdom
- Recruiting
- Research Site
-
Bath, United Kingdom
- Recruiting
- Research Site
-
Birmingham, United Kingdom
- Recruiting
- Research Site
-
Bournemouth, United Kingdom
- Recruiting
- Research Site
-
Cardiff, United Kingdom
- Recruiting
- Research Site
-
Conrnwall, United Kingdom
- Recruiting
- Research Site
-
Dartford, United Kingdom
- Recruiting
- Research Site
-
Derby, United Kingdom
- Recruiting
- Research Site
-
Doncaster, United Kingdom
- Recruiting
- Research Site
-
Dorset, United Kingdom
- Recruiting
- Research Site
-
Eastbourne, United Kingdom
- Recruiting
- Research Site
-
Hull, United Kingdom
- Recruiting
- Research Site
-
Lincoln, United Kingdom
- Recruiting
- Research Site
-
Liverpool, United Kingdom
- Recruiting
- Research Site
-
London, United Kingdom
- Recruiting
- Research Site
-
Mid Yorkshire, United Kingdom
- Recruiting
- Research Site
-
Middlesborough, United Kingdom
- Recruiting
- Research Site
-
Newcastle, United Kingdom
- Recruiting
- Research Site
-
North Shields, United Kingdom
- Recruiting
- Research Site
-
Norwich, United Kingdom
- Recruiting
- Research Site
-
Nottingham, United Kingdom
- Recruiting
- Research Site
-
Oxford, United Kingdom
- Recruiting
- Research Site
-
Plymouth, United Kingdom
- Recruiting
- Research Site
-
Southampton, United Kingdom
- Recruiting
- Research Site
-
Stockton on Tees, United Kingdom
- Recruiting
- Research Site
-
Stoke on Trent, United Kingdom
- Recruiting
- Research Site
-
Wigan, United Kingdom
- Recruiting
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 130 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Treatment-naïve adults (≥18 years old) with chronic lymphocytic lymphoma (CLL) who were initiated on acalabrutinib as part of the UK acalabrutiinib early access programme and received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021.
Description
The study population will include treatment-naïve patients with chronic lymphocytic lymphoma (CLL)* who meet the following inclusion criteria:
- Treatment-naïve CLL patients who were initiated on acalabrutinib as part of the UK Early Access Programme
- Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021
Patients aged ≥18 years old
- Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP.
Exclusion Criteria:
- None listed in study protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1
Patients with chronic lymphocytic leukaemia treated with acalabrutinib in first line
|
Acalabrutinib
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Real-world progression free survival (rwPFS)
Time Frame: 12 months
|
rwPFS will be defined as the time from index date until earliest record of real-world progression event as determined by physicians' assessment, or death (if no progression) or end of follow-up (for censored observations) whilst on first line treatment.
|
12 months
|
Real-world progression free survival (rwPFS)
Time Frame: 24 months
|
rwPFS will be defined as the time from index date until earliest record of real-world progression event as determined by physicians' assessment, or death (if no progression) or end of follow-up (for censored observations) whilst on first line treatment.
|
24 months
|
Real-world progression free survival (rwPFS)
Time Frame: 36 months
|
rwPFS will be defined as the time from index date until earliest record of real-world progression event as determined by physicians' assessment, or death (if no progression) or end of follow-up (for censored observations) whilst on first line treatment.
|
36 months
|
Real-world progression free survival (rwPFS)
Time Frame: 48 months
|
rwPFS will be defined as the time from index date until earliest record of real-world progression event as determined by physicians' assessment, or death (if no progression) or end of follow-up (for censored observations) whilst on first line treatment.
|
48 months
|
Real-world progression free survival (rwPFS)
Time Frame: 60 months
|
rwPFS will be defined as the time from index date until earliest record of real-world progression event as determined by physicians' assessment, or death (if no progression) or end of follow-up (for censored observations) whilst on first line treatment.
|
60 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Real-world overall survival (rwOS)
Time Frame: 12 months
|
rwOS will be defined as the time from index date up to death or last date the patient was known to be alive (for censored observations).
|
12 months
|
Real-world overall survival (rwOS)
Time Frame: 24 months
|
rwOS will be defined as the time from index date up to death or last date the patient was known to be alive (for censored observations).
|
24 months
|
Real-world overall survival (rwOS)
Time Frame: 36 months
|
rwOS will be defined as the time from index date up to death or last date the patient was known to be alive (for censored observations).
|
36 months
|
Real-world overall survival (rwOS)
Time Frame: 48 months
|
rwOS will be defined as the time from index date up to death or last date the patient was known to be alive (for censored observations).
|
48 months
|
Real-world overall survival (rwOS)
Time Frame: 60 months
|
rwOS will be defined as the time from index date up to death or last date the patient was known to be alive (for censored observations).
|
60 months
|
Real-world response rate (rwRR)
Time Frame: 12 months
|
rwRR will be defined as the proportion of patients with a recorded significant anti-cancer response and will be defined here as the sum of complete response, partial response and partial response + lymphocytosis.
Response will be based on the on the documented assessment of the local investigator.
|
12 months
|
Real-world response rate (rwRR)
Time Frame: 24 months
|
rwRR will be defined as the proportion of patients with a recorded significant anti-cancer response and will be defined here as the sum of complete response, partial response and partial response + lymphocytosis.
Response will be based on the on the documented assessment of the local investigator.
|
24 months
|
Real-world response rate (rwRR)
Time Frame: 36 months
|
rwRR will be defined as the proportion of patients with a recorded significant anti-cancer response and will be defined here as the sum of complete response, partial response and partial response + lymphocytosis.
Response will be based on the on the documented assessment of the local investigator.
|
36 months
|
Real-world response rate (rwRR)
Time Frame: 48 months
|
rwRR will be defined as the proportion of patients with a recorded significant anti-cancer response and will be defined here as the sum of complete response, partial response and partial response + lymphocytosis.
Response will be based on the on the documented assessment of the local investigator.
|
48 months
|
Real-world response rate (rwRR)
Time Frame: 60 months
|
rwRR will be defined as the proportion of patients with a recorded significant anti-cancer response and will be defined here as the sum of complete response, partial response and partial response + lymphocytosis.
Response will be based on the on the documented assessment of the local investigator.
|
60 months
|
Real-world clinical progression free survival 2 (rwPFS2)
Time Frame: 12 months
|
rwPFS2 will be defined as the time from index date to the date of the second record of real-world progression (as determined by physicians' assessment) or death due to any cause (if no progression), whichever occurs first whilst on second line treatment.
If there is no second progression or the patient is lost to follow-up, PFS2 will be censored at the time of the last available tumour assessment.
|
12 months
|
Real-world clinical progression free survival 2 (rwPFS2)
Time Frame: 24 months
|
rwPFS2 will be defined as the time from index date to the date of the second record of real-world progression (as determined by physicians' assessment) or death due to any cause (if no progression), whichever occurs first whilst on second line treatment.
If there is no second progression or the patient is lost to follow-up, PFS2 will be censored at the time of the last available tumour assessment.
|
24 months
|
Real-world clinical progression free survival 2 (rwPFS2)
Time Frame: 36 months
|
rwPFS2 will be defined as the time from index date to the date of the second record of real-world progression (as determined by physicians' assessment) or death due to any cause (if no progression), whichever occurs first whilst on second line treatment.
If there is no second progression or the patient is lost to follow-up, PFS2 will be censored at the time of the last available tumour assessment.
|
36 months
|
Real-world clinical progression free survival 2 (rwPFS2)
Time Frame: 48 months
|
rwPFS2 will be defined as the time from index date to the date of the second record of real-world progression (as determined by physicians' assessment) or death due to any cause (if no progression), whichever occurs first whilst on second line treatment.
If there is no second progression or the patient is lost to follow-up, PFS2 will be censored at the time of the last available tumour assessment.
|
48 months
|
Real-world clinical progression free survival 2 (rwPFS2)
Time Frame: 60 months
|
rwPFS2 will be defined as the time from index date to the date of the second record of real-world progression (as determined by physicians' assessment) or death due to any cause (if no progression), whichever occurs first whilst on second line treatment.
If there is no second progression or the patient is lost to follow-up, PFS2 will be censored at the time of the last available tumour assessment.
|
60 months
|
Frequency of acalabrutinib dose interruptions
Time Frame: Through study completion, an average of 5 years
|
A treatment interruption will be defined as clinician or patient-initiated temporary treatment cessation of acalabrutinib, where treatment is known to have been recommenced at any time within the observation window (without initiation on a different systemic treatment for CLL in the intervening period).
|
Through study completion, an average of 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Toby A Eyre, Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 17, 2022
Primary Completion (Estimated)
April 1, 2026
Study Completion (Estimated)
April 1, 2026
Study Registration Dates
First Submitted
August 24, 2022
First Submitted That Met QC Criteria
September 27, 2022
First Posted (Actual)
September 28, 2022
Study Record Updates
Last Update Posted (Actual)
February 15, 2024
Last Update Submitted That Met QC Criteria
February 14, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Leukemia, B-Cell
- Chronic Disease
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Antineoplastic Agents
- Acalabrutinib
Other Study ID Numbers
- D8220R00033
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia, CLL
-
AbbVieRecruitingCancer, Chronic Lymphocytic Leukemia (CLL)Korea, Republic of
-
Hackensack Meridian HealthCelgene CorporationTerminatedSmall Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia(CLL)United States
-
Piramal Enterprises LimitedDana-Farber Cancer Institute; Norris Cotton Cancer CenterSuspendedRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL)United States
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
Tampere University HospitalCompleted
-
AstraZenecaRecruitingChronic Lymphocytic Leukaemia (CLL)Germany
-
University of California, IrvineUnited States Department of DefenseActive, not recruitingAcute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, RefractoryUnited States
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.WithdrawnChronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | CLL/SLL | SLLUnited States
-
Novartis PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, ChronicUnited States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
-
AstraZenecaCLL ConsortiumCompletedB Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)United States
Clinical Trials on Acalabrutinib
-
AstraZenecaAcerta Pharma, LLCCompletedPharmacokinetics | BioavailabilityUnited States
-
AstraZenecaParexelCompletedCOVID-19 | Mantle Cell LymphomaGermany
-
Acerta Pharma BVAstraZenecaActive, not recruitingMantle Cell Lymphoma (MCL)United States, Poland, Italy
-
Acerta Pharma BVNational Institutes of Health (NIH)Active, not recruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Acerta Pharma BVAstraZenecaCompletedHepatic Insufficiency | Healthy Subjects | Hepatic ImpairmentUnited States
-
AstraZenecaCompletedBioequivalenceUnited States
-
AstraZenecaCompletedChronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell LymphomaIndia
-
Kartos Therapeutics, Inc.RecruitingChronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell LymphomaBelgium, Korea, Republic of, United States, United Kingdom, Italy, Switzerland, Australia, France, Poland, Portugal, Czechia
-
Acerta Pharma BVActive, not recruitingWaldenström Macroglobulinemia (WM)Spain, United States, United Kingdom, France, Italy, Greece, Netherlands
-
PETHEMA FoundationActive, not recruitingChronic Lymphocytic Leukemia- Binet Staging SystemSpain